×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
MYGN – myriad genetics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
MYGN
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/12
08:21 am
mygn
Ratio Therapeutics Appoints Global Medical Leader Colin Hayward as Chief Medical Officer [Yahoo! Finance]
Medium
Report
Ratio Therapeutics Appoints Global Medical Leader Colin Hayward as Chief Medical Officer [Yahoo! Finance]
3/11
01:03 pm
mygn
3 Reasons to Sell MYGN and 1 Stock to Buy Instead [Yahoo! Finance]
Medium
Report
3 Reasons to Sell MYGN and 1 Stock to Buy Instead [Yahoo! Finance]
3/11
11:15 am
mygn
Stocks making big moves yesterday: nLIGHT, Myriad Genetics, Vertex Pharmaceuticals, Nextpower, and Teladoc [Yahoo! Finance]
Low
Report
Stocks making big moves yesterday: nLIGHT, Myriad Genetics, Vertex Pharmaceuticals, Nextpower, and Teladoc [Yahoo! Finance]
3/10
03:30 pm
mygn
Myriad Genetics (MYGN) Shares Skyrocket, What You Need To Know [Yahoo! Finance]
Low
Report
Myriad Genetics (MYGN) Shares Skyrocket, What You Need To Know [Yahoo! Finance]
3/6
08:31 am
mygn
2 Unprofitable Stocks on Our Buy List and 1 We Brush Off [Yahoo! Finance]
Low
Report
2 Unprofitable Stocks on Our Buy List and 1 We Brush Off [Yahoo! Finance]
3/3
05:19 pm
mygn
Myriad Genetics (MYGN) Stock Trades Up, Here Is Why [Yahoo! Finance]
Low
Report
Myriad Genetics (MYGN) Stock Trades Up, Here Is Why [Yahoo! Finance]
3/2
04:40 pm
mygn
Myriad Commercially Launches Precise MRD with Select Community Oncologists [Yahoo! Finance]
Medium
Report
Myriad Commercially Launches Precise MRD with Select Community Oncologists [Yahoo! Finance]
3/2
04:05 pm
mygn
Myriad Commercially Launches Precise MRD with Select Community Oncologists
Medium
Report
Myriad Commercially Launches Precise MRD with Select Community Oncologists
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
3/9
07:03 pm
mygn
Form 4 MYRIAD GENETICS INC For: Mar 09 Filed by: Raha Samraat S.
Medium
Report
Form 4 MYRIAD GENETICS INC For: Mar 09 Filed by: Raha Samraat S.
3/2
04:19 pm
mygn
Form 4 MYRIAD GENETICS INC For: Mar 01 Filed by: Solaiman Shereen
Medium
Report
Form 4 MYRIAD GENETICS INC For: Mar 01 Filed by: Solaiman Shereen
2/27
04:46 pm
mygn
Form 4 MYRIAD GENETICS INC For: Feb 25 Filed by: Phanstiel S. Louise
Medium
Report
Form 4 MYRIAD GENETICS INC For: Feb 25 Filed by: Phanstiel S. Louise
2/24
04:02 pm
mygn
Form 10-K MYRIAD GENETICS INC For: Dec 31
Medium
Report
Form 10-K MYRIAD GENETICS INC For: Dec 31
2/23
04:08 pm
mygn
Form 8-K MYRIAD GENETICS INC For: Feb 23
Medium
Report
Form 8-K MYRIAD GENETICS INC For: Feb 23
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
8/1
Form 8-K MYRIAD GENETICS INC For: Aug 01
55.0%
4/6 Myriad Receives Reimbursement for the BRACAnalysis® Diagnostic System in Japan for Patients with Breast or Ovarian Cancer Associated with HBOC 25.2%
3/23 Myriad Announces Board of Directors Leadership Transition 12.5%
11/6 GeneSight® Psychotropic Test Improved Clinical Outcomes for People with Depression Who Were Taking Medications with Gene-Drug Interactions 11.5%
8/16 Myriad Genetics, Inc. (NASDAQ: MYGN) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. 8.6%
12/4 Myriad’s Prequel™ Prenatal Screen has Superior Sensitivity in Women with High BMI Undergoing Non-Invasive Prenatal Screening 7.9%
3/25 Myriad Genetics, Inc. (NASDAQ: MYGN) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. 7.1%
8/2 Myriad Genetics, Inc. (NASDAQ: MYGN) was upgraded by analysts at Bank of America Corp from an "underperform" rating to a "neutral" rating. 6.8%
11/23 DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Myriad Genetics, Inc. and Encourages Investors to Contact the Firm 6.4%
4/28 Myriad to Announce Fiscal Third-Quarter 2020 Financial Results on May 5, 2020 6.2%
4/6 Myriad Receives Reimbursement for the BRACAnalysis® Diagnostic System in Japan for Patients with Breast or Ovarian Cancer Associated with HBOC 25.2%
3/23 Myriad Announces Board of Directors Leadership Transition 12.5%
11/6 GeneSight® Psychotropic Test Improved Clinical Outcomes for People with Depression Who Were Taking Medications with Gene-Drug Interactions 11.5%
8/16 Myriad Genetics, Inc. (NASDAQ: MYGN) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. 8.6%
12/4 Myriad’s Prequel™ Prenatal Screen has Superior Sensitivity in Women with High BMI Undergoing Non-Invasive Prenatal Screening 7.9%
3/25 Myriad Genetics, Inc. (NASDAQ: MYGN) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. 7.1%
8/2 Myriad Genetics, Inc. (NASDAQ: MYGN) was upgraded by analysts at Bank of America Corp from an "underperform" rating to a "neutral" rating. 6.8%
11/23 DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Myriad Genetics, Inc. and Encourages Investors to Contact the Firm 6.4%
4/28 Myriad to Announce Fiscal Third-Quarter 2020 Financial Results on May 5, 2020 6.2%
TOP News Decliners
8/13
Q4/2019 6/30/2019 EPS 0.410 ZacksConsensus 0.400 ActVsEst 0.010 - Beat
-42.8%
11/4 Q1/2020 9/30/2019 EPS 0.080 ZacksConsensus 0.260 ActVsEst (0.180) - Miss -40.1%
2/6 Q2/2020 12/31/2019 EPS 0.230 ZacksConsensus 0.220 ActVsEst 0.010 - Beat -28.2%
5/7 Form 8-K MYRIAD GENETICS INC For: May 07 -21.4%
8/14 Myriad Genetics, Inc. (NASDAQ: MYGN) was downgraded by analysts at Barclays PLC from an "equal weight" rating to an "underweight" rating. -9.9%
8/22 Myriad Applauds the U.S. Preventive Services Task Force Recommendation on BRCA-Related Cancer Prevention -8.1%
6/14 Myriad Genetics, Inc. (NASDAQ: MYGN) had its price target raised by analysts at Barclays PLC from $18.00 to $20.00. They now have an "underweight" rating on the stock. -7.7%
2/7 Myriad Genetics, Inc. (NASDAQ: MYGN) had its price target lowered by analysts at Piper Sandler from to . -6.3%
3/17 Myriad Genetics, Inc. (NASDAQ: MYGN) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. -6.0%
8/7 Myriad Will Seek FDA Approval of BRACAnalysis CDx® As a Companion Diagnostic for Lynparza® (olaparib) In Men with Metastatic Castrate-Resistant Prostate Cancer -4.6%
11/4 Q1/2020 9/30/2019 EPS 0.080 ZacksConsensus 0.260 ActVsEst (0.180) - Miss -40.1%
2/6 Q2/2020 12/31/2019 EPS 0.230 ZacksConsensus 0.220 ActVsEst 0.010 - Beat -28.2%
5/7 Form 8-K MYRIAD GENETICS INC For: May 07 -21.4%
8/14 Myriad Genetics, Inc. (NASDAQ: MYGN) was downgraded by analysts at Barclays PLC from an "equal weight" rating to an "underweight" rating. -9.9%
8/22 Myriad Applauds the U.S. Preventive Services Task Force Recommendation on BRCA-Related Cancer Prevention -8.1%
6/14 Myriad Genetics, Inc. (NASDAQ: MYGN) had its price target raised by analysts at Barclays PLC from $18.00 to $20.00. They now have an "underweight" rating on the stock. -7.7%
2/7 Myriad Genetics, Inc. (NASDAQ: MYGN) had its price target lowered by analysts at Piper Sandler from to . -6.3%
3/17 Myriad Genetics, Inc. (NASDAQ: MYGN) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. -6.0%
8/7 Myriad Will Seek FDA Approval of BRACAnalysis CDx® As a Companion Diagnostic for Lynparza® (olaparib) In Men with Metastatic Castrate-Resistant Prostate Cancer -4.6%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: